KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Debt to Equity (2019 - 2025)

Vir Biotechnology (VIR) has disclosed Debt to Equity for 5 consecutive years, with $0.02 as the latest value for Q1 2025.

  • Quarterly Debt to Equity changed N/A to $0.02 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $0.02 through Mar 2025, changed N/A year-over-year, with the annual reading at $0.01 for FY2024, N/A changed from the prior year.
  • Debt to Equity hit $0.02 in Q1 2025 for Vir Biotechnology, up from $0.01 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.08 in Q3 2021 to a low of $0.01 in Q4 2024.
  • Historically, Debt to Equity has averaged $0.04 across 3 years, with a median of $0.04 in 2021.
  • Biggest YoY gain for Debt to Equity was 326.24% in 2021; the steepest drop was 33.24% in 2021.
  • Year by year, Debt to Equity stood at $0.08 in 2021, then plummeted by 82.14% to $0.01 in 2024, then grew by 20.09% to $0.02 in 2025.
  • Business Quant data shows Debt to Equity for VIR at $0.02 in Q1 2025, $0.01 in Q4 2024, and $0.08 in Q3 2021.